GET DAILY SIGNALSMacroGenics (MGNX) Slides -40% After Mixed ESMO 2026 Data
Key Takeaways
- MacroGenics shares fell roughly 40% over the past 30 days, sliding from about $4.06 to $2.44 as of the latest close.
- The decline was driven primarily by data readouts at the ESMO 2026 Congress for two pipeline programs, MGC026 and lorigerlimab.
- Safety concerns, including a treatment-related death and high rates of severe side effects, overshadowed encouraging efficacy signals.
- The stock is also down roughly 37% over the last quarter, extending a broader multi-month pullback.
- The company's partnerships with Incyte, Sanofi, and Gilead remain key sources of milestone and royalty income, with cash runway guided through 2028.
- Investors can find more details on this ticker's Price Targets, Earnings, and Forecast on additional pages.
- For automated trading ideas across the broader market, explore Trending AI Robots.
MacroGenics (MGNX) Overview and Market Position
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer. The company builds its pipeline from proprietary technology platforms, including its DART and TRIDENT multi-specific antibody platforms and a portfolio of topoisomerase I inhibitor-based antibody-drug conjugates (ADCs). Its pipeline includes MGC026, a B7-H3-directed ADC; MGC028, targeting ADAM9; MGC030, directed against an undisclosed target; and lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4.
Beyond its internal programs, MGNX maintains collaborations with Incyte Corporation, Sanofi, and Gilead Sciences spanning commercial, clinical, and preclinical programs. These partnerships cover products such as ZYNYZ (retifanlimab-dlwr), TZIELD (teplizumab-mzwv), and MGD024. Across these agreements, the company has said it remains eligible for up to approximately $2.5 billion in aggregate future milestones plus royalties on partnered products, positioning it as a small-cap biotech with a royalty-driven revenue component.
MacroGenics (MGNX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MGNX has fallen approximately 40%, moving from a close near $4.06 to about $2.44. The bulk of the decline was concentrated around the ESMO 2026 Congress in late October, when the stock dropped sharply over a matter of sessions following clinical data presentations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture tells a similar story. Measured over roughly the last three months, the stock is down about 37%, having traded near $3.85 in late July before a volatile stretch that included a mid-summer slide, a partial recovery through September, and the sharp October sell-off. The trend highlights that the recent weakness is not purely a single-session event but part of a broader downward trajectory in the share price.
What Drove MGNX Stock Price in the Last 30 Days
The primary catalyst was the company's clinical data presented at the ESMO 2026 Congress in Madrid. On October 23, MacroGenics shared interim Phase 1 data for MGC026 in advanced solid tumors. The results showed a 29% confirmed objective response rate in dose escalation and a 27% response rate in the head and neck cancer cohort, with no cases of interstitial lung disease, pneumonitis, or ocular toxicity. Despite these encouraging efficacy signals, the shares fell sharply, suggesting investors focused on safety and competitive positioning concerns.
The more consequential readout came with interim Phase 2 LINNET data for lorigerlimab in clear cell gynecologic cancer. The study reported a 25% confirmed objective response rate and 44% disease control rate, but also disclosed that 49% of patients experienced Grade 3 or higher treatment-related adverse events, including one treatment-related death in the platinum-resistant ovarian cancer cohort. Treatment-related events led to discontinuation in 24% of patients. The company said it would enroll additional patients at a lower dose and no longer pursue development in platinum-resistant ovarian cancer. The safety profile, particularly the high rate of severe side effects and the reported death, outweighed the efficacy data and drove the stock lower.
What Drove MGNX Stock Performance Over the Last Quarter
The broader three-month decline reflects a shift in sentiment around the company's pipeline and its transition to a leaner operating model. During the quarter, MacroGenics completed the sale of its manufacturing operations to Bora Pharmaceuticals for $122.5 million and expanded a royalty monetization agreement tied to ZYNYZ with Sagard Healthcare Partners, strengthening its balance sheet and extending its cash runway through 2028. These transactions provided non-dilutive capital but also marked a strategic pivot to a fully outsourced manufacturing model.
At the same time, the market has weighed clinical risk across the ADC and bispecific pipeline. Positive preclinical and early-stage momentum, including the first patient dosed in a Phase 1 study of MGC030, was offset by uncertainty ahead of the ESMO data and, ultimately, by the safety signals that emerged from the lorigerlimab readout. The result has been a steady de-rating of the stock even as the company's pro forma cash position remained substantial relative to its market capitalization.
MGNX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important factors for MacroGenics are clinical execution and safety. Investors will watch for updated LINNET results from the lower 3 mg/kg dose cohort, expected in the first half of 2027, and for further data on MGC026 in head and neck cancer and other tumor types, also anticipated in 2027. The company's plan to initiate an expansion cohort combining MGC026 with pembrolizumab in earlier-line treatment represents a key development milestone. From what I see, these upcoming readouts will be critical in shaping the next phase of sentiment.
Financial considerations also remain relevant. Continued milestone and royalty payments from the Incyte, Sanofi, and Gilead collaborations, along with the cash runway guided through 2028, will shape how the market views the company's funding risk. Regulatory decisions, competitive developments in the ADC and bispecific space, and broader biotech sector sentiment could also influence the stock. As with all clinical-stage biotechs, trial outcomes and safety data remain the dominant variables.
Using Tickeron AI Tools for Market Insights
In my own research process, I frequently turn to Tickeron’s AI Trading Bots to supplement manual analysis with automated signals across a wide range of tickers. The platform offers hundreds of bots with varying strategies and timeframes, allowing users to compare performance metrics and identify relevant ideas quickly. This approach provides a useful data-driven layer when evaluating names like MGNX alongside broader market trends. For more details, visit Trending AI Robots.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MGNX sees its Stochastic Oscillator ascends from oversold territory
On October 21, 2026, the Stochastic Oscillator for MGNX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In 58 of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 77 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for MGNX turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 45 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
MGNX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.625) is normal, around the industry mean (3.037). P/E Ratio (-11.091) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology
Advertisement